Literature DB >> 12849396

Epilepsy in autism.

Roberto Tuchman1, Isabelle Rapin.   

Abstract

There is an increased but variable risk of epilepsy in autism. Three main factors--age, cognitive level, and type of language disorder--account for variability in the reported prevalence of epilepsy. The prevalence is highest in studies that have included adolescents and young adults, individuals with moderate to severe mental retardation and those with motor deficits, and individuals with severe receptive language deficits. The association of autism with clinical or subclinical epilepsy might denote common genetic factors in some cases. Whether subclinical epilepsy has adverse effects on cognition, language, and behaviour is debated, as is the relation of autistic regression with an epileptiform electroencephalogram to Landau-Kleffner syndrome. There is no evidence-based treatment recommendation for individuals with autism, regression, and subclinical epilepsy. Double-blind studies with sufficient power to resolve this issue are urgently needed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12849396     DOI: 10.1016/s1474-4422(02)00160-6

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  192 in total

1.  Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial.

Authors:  Barry Wright; David Sims; Siobhan Smart; Ahmed Alwazeer; Ben Alderson-Day; Victoria Allgar; Clare Whitton; Heather Tomlinson; Sophie Bennett; Jenni Jardine; Nicola McCaffrey; Charlotte Leyland; Christine Jakeman; Jeremy Miles
Journal:  J Autism Dev Disord       Date:  2011-02

2.  Early-life seizures result in deficits in social behavior and learning.

Authors:  Joaquin N Lugo; John W Swann; Anne E Anderson
Journal:  Exp Neurol       Date:  2014-03-29       Impact factor: 5.330

3.  Sodium phenylbutyrate reduces repetitive self-grooming behavior and rescues social and cognitive deficits in mouse models of autism.

Authors:  Young-Kyoung Ryu; Hye-Yeon Park; Jun Go; Dong-Hee Choi; Young-Keun Choi; Myungchull Rhee; Chul-Ho Lee; Kyoung-Shim Kim
Journal:  Psychopharmacology (Berl)       Date:  2021-03-16       Impact factor: 4.530

4.  Risk and correlates of autism spectrum disorder in children with epilepsy: a community-based study.

Authors:  Anne T Berg; Sigita Plioplys; Roberto Tuchman
Journal:  J Child Neurol       Date:  2011-03-18       Impact factor: 1.987

5.  Searching for autism symptomatology in children with epilepsy--a new approach to an established comorbidity.

Authors:  Beth A Malow
Journal:  Epilepsy Curr       Date:  2006 Sep-Oct       Impact factor: 7.500

6.  Glyoxalase I polymorphism rs2736654 causing the Ala111Glu substitution modulates enzyme activity--implications for autism.

Authors:  Madhabi Barua; Edmund C Jenkins; Wenqiang Chen; Salomon Kuizon; Raju K Pullarkat; Mohammed A Junaid
Journal:  Autism Res       Date:  2011-04-12       Impact factor: 5.216

7.  Comorbidity clusters in autism spectrum disorders: an electronic health record time-series analysis.

Authors:  Finale Doshi-Velez; Yaorong Ge; Isaac Kohane
Journal:  Pediatrics       Date:  2013-12-09       Impact factor: 7.124

8.  Epilepsy among children and adolescents with autism spectrum disorders: a population-based study.

Authors:  Elina Jokiranta; Andre Sourander; Auli Suominen; Laura Timonen-Soivio; Alan S Brown; Matti Sillanpää
Journal:  J Autism Dev Disord       Date:  2014-10

9.  Brief Report: Prevalence of Co-occurring Epilepsy and Autism Spectrum Disorder: The U.S. National Survey of Children's Health 2011-2012.

Authors:  Shiny Thomas; Mary E Hovinga; Dheeraj Rai; Brian K Lee
Journal:  J Autism Dev Disord       Date:  2017-01

Review 10.  Exploring the multifactorial nature of autism through computational systems biology: calcium and the Rho GTPase RAC1 under the spotlight.

Authors:  Fares Zeidán-Chuliá; José Luiz Rybarczyk-Filho; Alla B Salmina; Ben-Hur Neves de Oliveira; Mami Noda; José Cláudio F Moreira
Journal:  Neuromolecular Med       Date:  2013-03-02       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.